Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMV/EBV Specific T-cells for Prevention of Viral Reactivation After Allo-SCT
NCT02227641Phase 2Completed
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Oct 2014
- Primary completion
- Oct 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cytomegalovirus-specific T-cells + epstein-barr virus-specific T-cells in cytomegalovirus infection (CMV), Epstein-Barr virus infection, sponsored by FAU Erlangen-Nürnberg Medical Faculty. Started Oct 2014; status: completed.
02
Drugs
cytomegalovirus-specific T-cells + epstein-barr virus-specific T-cells
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT02227641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227641.